Arnaldo Moura Neto

Arnaldo Moura Neto

Auto-generated profile, based on publicly available information

Arnaldo Moura Neto

Discipline of Endocrinology, Internal Medicine Department, Faculty of Medical Sciences, University of Campinas, Campinas, Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2016 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MPMaria Candida R. Parisi
Maria Candida R. Parisi
ANArnaldo Moura Neto
Arnaldo Moura Neto
FMFabio H. Menezes
Fabio H. Menezes
MGMARILIA GOMES
MARILIA GOMES
RTRodrigo Martins Teixeira
Rodrigo Martins Teixeira
MSMario Saad
Mario Saad
Studies on diabetic foot and its complications involving a significant and representative sample of patients in South American countries are scarce. The main objective of this study was to acquire clinical and epidemiological data on a large cohort of diabetic patients from 19 centers from Brazil and focus on factors that could be associated with the risk of ulcer and amputation. This study presents cross sectional, baseline results of the BRAZUPA Study. A total of 1455 patients were included. Parameters recorded included age, gender, ethnicity, diabetes and comorbidity-related records, previous ulcer or amputation, clinical symptomatic score, foot classification and microvascular complications. Patients with ulcer had longer disease duration (17.2 ± 9.9 vs. 13.2 ± 9.4 years; p < 0.001), and poorer glycemic control (HbA1c 9.23 ± 2.03 vs. 8.35 ± 1.99; p < 0.001). Independent risk factors for ulcer were male gender (OR 1.71; 95 % CI 1.2–3.7), smoking (OR 1.78; 95 % CI 1.09–2.89), neuroischemic foot (OR 20.34; 95 % CI 9.31–44.38), region of origin (higher risk for those from developed regions, OR 2.39; 95 % CI 1.47–3.87), presence of retinopathy (OR 1.68; 95 % CI 1.08–2.62) and absence of vibratory sensation (OR 7.95; 95 % CI 4.65–13.59). Risk factors for amputation were male gender (OR 2.12; 95 % CI 1.2–3.73), type 2 diabetes (OR 3.33; 95 % CI 1.01–11.1), foot at risk classification (higher risk for ischemic foot, OR 19.63; 95 % CI 3.43–112.5), hypertension (lower risk, OR 0.3; 95 % CI 0.14–0.63), region of origin (South/Southeast, OR 2.2; 95 % CI 1.1–4.42), previous history of ulcer (OR 9.66; 95 % CI 4.67–19.98) and altered vibratory sensation (OR 3.46; 95 % CI 1.64–7.33). There was no association between either outcome and ethnicity. Ulcer and amputation rates were high. Age at presentation was low and patients with ulcer presented a higher prevalence of neuropathy compared to ischemic foot at risk. Ischemic disease was more associated with amputations. Ethnical differences were not of great importance in a miscegenated population.

10 October 2016 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
ANArnaldo Moura Neto
Arnaldo Moura Neto
DZDenise Engelbrecht Zantut-Wittmann
Denise Engelbrecht Zantut-Wittmann
Thyroid hormone abnormalities are common in critically ill patients. For over three decades, a mild form of these abnormalities has been described in patients with several diseases under outpatient care. These alterations in thyroid hormone economy are a part of the nonthyroidal illness and keep an important relationship with prognosis in most cases. The main feature of this syndrome is a fall in free triiodothyronine (T3) levels with normal thyrotropin (TSH). Free thyroxin (T4) and reverse T3 levels vary according to the underlying disease. The importance of recognizing this condition in such patients is evident to physicians practicing in a variety of specialties, especially general medicine, to avoid misdiagnosing the much more common primary thyroid dysfunctions and indicating treatments that are often not beneficial. This review focuses on the most common chronic diseases already known to present with alterations in serum thyroid hormone levels. A short review of the common pathophysiology of the nonthyroidal illness is followed by the clinical and laboratorial presentation in each condition. Finally, a clinical case vignette and a brief summary on the evidence about treatment of the nonthyroidal illness and on the future research topics to be addressed are presented.

3 November 2012 in Endocrine
Verified
Journal Article
Closed access
PDF file
ANArnaldo Moura Neto
Arnaldo Moura Neto
DZDenise Engelbrecht Zantut-Wittmann
Denise Engelbrecht Zantut-Wittmann
TFTulio Diniz Fernandes
Tulio Diniz Fernandes
MNMarcia Nery
Marcia Nery
MPMaria Candida Ribeiro Parisi
Maria Candida Ribeiro Parisi

1 May 2012 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
AMArnaldo Moura-Neto
Arnaldo Moura-Neto
TFTulio Diniz Fernandes
Tulio Diniz Fernandes
DZDenise Engelbrecht Zantut-Wittmann
Denise Engelbrecht Zantut-Wittmann
RTRafael Ortiz Trevisan
Rafael Ortiz Trevisan
MSMarcos Hideyo Sakaki
Marcos Hideyo Sakaki
MPMaria Candida Ribeiro Parisi
Maria Candida Ribeiro Parisi

1 June 2012 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
AMArnaldo Moura-Neto
Arnaldo Moura-Neto
CMCamila Mosci
Camila Mosci
ASAllan O. Santos
Allan O. Santos
BABarbara J. Amorim
Barbara J. Amorim
MLMariana C. L. de Lima
Mariana C. L. de Lima
DZDenise Engelbrecht Zantut-Wittmann
Denise Engelbrecht Zantut-Wittmann
Purpose To investigate the factors influencing the success rate in a fixed, 15 mCi approach for treatment of Graves’ hyperthyroidism. Material and Methods The thyroid function outcome (hyperthyroidism or euthyroidism/hypothyroidism) was verified at least 1 year after radioiodine therapy (RIT) retrospectively and compared with presenting clinical characteristics and pre-RIT parameters in 87 patients treated with 131I-iodide for Graves’ disease in a tertiary care center. Results After RIT, 16 patients (18.4%) became euthyroid, 54 patients (62.1%) became hypothyroid, and 17 (19.5%) remained hyperthyroid. We found no statistically significant association between thyroid function outcome and gender (P = 0.50), ophthalmopathy (P = 0.69), drug used (methimazole or propylthiouracil; P = 1.00), maintenance or withdrawal of thionamides pre-RIT (P = 0.98), or 99mTc sodium pertechnetate thyroid uptake prior to RIT (P = 0.75). The only variable associated with the success rate was thyroid mass <62 g (P < 0.001). Conclusions Our study has shown that a fixed 15 mCi approach for treatment of Graves’ disease was effective, but high failure rates were observed in patients presenting larger goiters, particularly those with estimated thyroid mass >62 g.

25 May 2013 in ISRN Endocrinology
Verified
Journal Article
Open access
PDF file
PLPriscila Carneiro Moreira Lima
Priscila Carneiro Moreira Lima
ANArnaldo Moura Neto
Arnaldo Moura Neto
MTMarcos Antonio Tambascia
Marcos Antonio Tambascia
DZDenise Engelbrecht Zantut-Wittmann
Denise Engelbrecht Zantut-Wittmann
Objectives. Assess the prevalence of thyroid nodules and predictors of malignant origin in patients with autoimmune thyroid diseases. Patients and Methods. Retrospective study including 275 patients, 198 with Graves' disease and 77 with Hashimoto’s thyroiditis. Clinical and demographical data, ultrasonographical nodule characteristics, total thyroid volume and histological characteristics were recorded. Results. Graves’ disease: the prevalence of thyroid nodules and thyroid carcinoma were 27.78% and 5.05%, respectively. Older age (OR = 1.054; 95% CI = 1.029–1.080) and larger thyroid volumes (OR = 1.013; 95% CI = 1.003–1.022) increased the chance of nodules. Younger age (OR = 1.073; 95% CI = 1.020–1.128) and larger thyroid volume (OR = 1.018; 95% CI = 1.005–1.030) predicted thyroid carcinoma. Hashimoto’s thyroiditis: the prevalence of thyroid nodules and carcinomas were 50.7% and 7.8%, respectively. Nodules were predicted by thyroid volume (OR = 1.030; 95% CI = 1.001–1.062). We found higher number of nodules in patients with thyroid carcinoma than in those with benign nodules (3 versus 2; ). Patients with Hashimoto’s thyroiditis presented nodules more frequently than patients with Graves’ disease (50.65% versus 27.28%; ), while the prevalence of carcinoma was similar (). Conclusions. Larger goiter was associated with carcinoma in Graves’ disease and Hashimoto’s thyroiditis. Younger patients presented higher risk of papillary thyroid carcinoma in Graves’ disease. The prevalence of carcinoma was similar in both conditions.